
SEP 0 4 2001



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

RECEIVED

Nabil Hanna et al.

Group Art Unit: 1644

SEP 0 6 2001

Application Serial No. 09/435,992

Examiner: P. Gambel

TECH CENTER 1600/2900

Filed: November 8, 1999

Title: Treatment of B Cell Malignancies Using Anti-CD40L Antibodies in Combination

WITH ANTI-CD20 ANTIBODIES AND/OR CHEMOTHERAPEUTICS AND RADIOTHERAPY

* * * *

4/13/01

ELECTION

Hon. Commissioner of Patents Washington, D.C. 20231

Sir:

In response to the Official Action [Restriction Requirement] dated July 3, 2001, Applicants submit the following amendments and remarks.

In the Claims:

Please cancel non-elected Claims 42-56 without prejudice or disclaimer.

Please enter the following new Claims:

- --57. The method of Claim 10, wherein the chemotherapeutic agent for treating leukemia is an alkylating agent.
- The combination therapy of Claim 27, wherein the B-cell leukemia is a chronic B-cell leukemia, acute lymphoblastic leukemia of a B-cell lineage, or chronic lymphopcytic leukemia of a B-cell lineage.
- 59. The combination therapy of Claim 58, wherein the chemotherapeutic agent for trating a B-cell leukemia is selected from the group consisting of cyclophosphamide; CHOP; CMP; CVP; and CAP.--

0000075001 MARLEIR1 00000000 09735999

01 F0:115

110.00 un